Spectrum Pharmaceuticals

From Wikipedia, the free encyclopedia
Spectrum Pharmaceuticals, Inc.
TypePublic
IndustryPharmaceuticals
HeadquartersHenderson, Nevada, U.S.
Key people
Joseph Turgeon, Chief Executive Officer
RevenueDecrease US$109.33 million (2018)
Number of employees
Increase 235 (December 31, 2018)
Websitesppirx.com

Spectrum Pharmaceuticals is an American biopharmaceutical company. The company is located in Irvine, California.

Drugs[]

Spectrum develops and markets drugs for treatments in oncology.

Approved drugs[]

  • Fusilev (Levoleucovorin) for injection is a drug that was approved by the U.S. Food and Drug Administration in 2008 for the US; the drug had been on the market in a number of European countries.[citation needed]
  • Folotyn (pralatrexate) is an antifolate drug marketed for relapsed or refractory peripheral T-cell lymphoma.
  • Khapzory (levoleucovorin) (Disodium Levoleucovorin), for injection, a folate analog for three indications:
    • Rescue after high-dose methotrexate therapy in patients with osteosarcoma.
    • Diminishing the toxicity associated with overdosage of folic acid antagonists or impaired methotrexate elimination.
    • The treatment of patients with metastatic colorectal cancer in combination with fluorouracil.
  • Zevalin (ibritumomab) is indicated for the treatment of patients with relapsed or refractory, low‑grade or follicular B‑cell non‑Hodgkin's lymphoma (NHL), including patients with rituximab-refractory follicular NHL. It is a CD-20 radio-antibody.[1]
  • Marqibo (Vincristine sulfate liposomes injection) is a sphingomyelin/cholesterol liposome-encapsulated formulation of the FDA-approved anticancer drug vincristine. Marqibo's approved indication is for the treatment of adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia (Ph- ALL) in second or greater relapse or whose disease has progressed following two or more lines of anti-leukemia therapy. It was approved by the FDA in 2012.[2]
  • Beleodaq (belinostat) is an HDAC inhibitor for relapsed or refractory peripheral T-cell lymphoma.
  • Evomela (melphalan) is an alkalyating drug for multiple myeloma.[1]

In development[]

As of 2019, a number of drugs are investigated in clinical trials.[3]

  • Qapzola (apaziquone) is a synthetic bio-reductive prodrug intended for the treatment of non-invasive bladder cancer that is currently in Phase 3 studies. Allergan invested money in 2008 to help develop this medication further and bring it to the market.[4]
  • Rolontis (eflapegrastim) is in phase III trials for treatment of chemotherapy-induced neutropenia.[5]
  • Poziotinib is a quinazoline-based pan-HER inhibitor that blocks signaling through HER tyrosine-kinase receptors including HER1 (erbB1; EGFR), HER2 (erbB2), and HER4 (erbB4). It is currently in phase II trials.

Spectrum terminated the development of Ozarelix, a luteinizing hormone releasing hormone antagonist for the treatment of benign prostatic hypertrophy in 2010.[6] Other previous drug candidates included ortataxel for the treatment of taxane-refractory tumors, and satraplatin for non-small cell lung cancer.

References[]

  1. ^ Jump up to: a b [1][dead link]
  2. ^ "Spectrum Pharmaceuticals Launches Marqibo® (vinCRIStine sulfate LIPOSOME injection) and Ships First Commercial Orders". Businesswire.com. 3 September 2013. Retrieved 2 June 2019.
  3. ^ "Search of: Recruiting, Not yet recruiting, Available Studies - spectrum pharmaceuticals - List Results". Clinicaltrials.gov. Retrieved 2 June 2019.
  4. ^ Marcial G (June 15, 2009). "Cancer drugs from Spectrum". Businessweek: 67.
  5. ^ "RAnDomized Trial of SPI-2012 Versus Pegfilgrastim in the Management of Chemotherapy Induced Neutropenia in Breast CANCEr Patients Receiving Docetaxel and Cyclophosphamide - Full Text View". Clinicaltrials.gov. Retrieved 2 June 2019.
  6. ^ "Spectrum Pharmaceuticals Terminates Ozarelix Development Program in Benign Prostate Hypertrophy (BPH) as It Continues to Prioritize Its Portfolio Strategy". Businesswire.com. 27 January 2010. Retrieved 2 June 2019.

External links[]

Retrieved from ""